<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ani Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc</link>
<description>Latest news and press releases for Ani Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 10:50:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ani-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835466178dffbe2df0e2f5e.webp</url>
<title>Ani Pharmaceuticals Inc</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc</link>
</image>
<item>
<title>ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-to-discuss-first-quarter-2026-financial-results-on-may-8-2026-at-800-am-et</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-to-discuss-first-quarter-2026-financial-results-on-may-8-2026-at-800-am-et</guid>
<pubDate>Fri, 24 Apr 2026 10:50:00 GMT</pubDate>
<description>PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results. To view the we</description>
</item>
<item>
<title>ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-pimozide-tablets-with-180-day-cgt-exclusivity</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-pimozide-tablets-with-180-day-cgt-exclusivity</guid>
<pubDate>Mon, 20 Apr 2026 10:50:00 GMT</pubDate>
<description>PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic version of the reference listed drug (RLD) Orap®. "We are proud to announce the launch of Pimozide Tablets with 180-Day CGT exclusivity. We are excited to bring limited competition products to market and continue to provide generic alternatives to our customers and patients,” stated Ni</description>
</item>
<item>
<title>ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-the-launch-of-carbamazepine-extended-release-capsules</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-the-launch-of-carbamazepine-extended-release-capsules</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine</description>
</item>
<item>
<title>ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-fda-approval-and-launch-of-isosorbide-mononitrate-tablet</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-fda-approval-and-launch-of-isosorbide-mononitrate-tablet</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final</description>
</item>
<item>
<title>ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-publication-of-new-day-clinical-trial-results-in-ophthalmology</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-publication-of-new-day-clinical-trial-results-in-ophthalmology</guid>
<pubDate>Tue, 07 Apr 2026 10:50:00 GMT</pubDate>
<description>PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in appropriate patients with diabetic macular edema in Ophthalmology, the journal of the American Academy of Ophthalmology. The company previously announced results from the NEW DAY trial in July 2025. ILUVIEN is a cort</description>
</item>
<item>
<title>ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026-financial-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026-financial-guidance</guid>
<pubDate>Fri, 27 Feb 2026 11:50:00 GMT</pubDate>
<description>Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9</description>
</item>
<item>
<title>ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-discuss-fourth-quarter-115000758</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-discuss-fourth-quarter-115000758</guid>
<pubDate>Fri, 13 Feb 2026 11:50:00 GMT</pubDate>
<description>PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as foll</description>
</item>
<item>
<title>ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-highlights-significant-growth-115000969</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-highlights-significant-growth-115000969</guid>
<pubDate>Mon, 12 Jan 2026 11:50:00 GMT</pubDate>
<description>For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectivelyRare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, unaudited resultsProvides full ye</description>
</item>
<item>
<title>ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani,</description>
</item>
<item>
<title>ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-formation-futurevision-advisory-council-help</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-formation-futurevision-advisory-council-help</guid>
<pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
<description>Expert retina and uveitis specialists will help support the growth and innovation of ANI’s ophthalmology and retina franchise for a meaningful impact on</description>
</item>
<item>
<title>ANI Pharmaceuticals Announces Board Transition</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-board-transition-2025-12-01</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-board-transition-2025-12-01</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>Patrick D. Walsh steps down as Chairman and will complete his current term as Board memberThomas J. Haughey has been unanimously elected to serve as the next</description>
</item>
<item>
<title>ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-present-piper-sandler-37th-annual-healthcare-conference-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-present-piper-sandler-37th-annual-healthcare-conference-2025-11</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief</description>
</item>
<item>
<title>ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-present-jefferies-global-healthcare-conference-london-2025-11-11</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-present-jefferies-global-healthcare-conference-london-2025-11-11</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief</description>
</item>
<item>
<title>ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-reports-record-third-quarter-2025-financial-results-and-raises</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-reports-record-third-quarter-2025-financial-results-and-raises</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-yearPurified Cortrophin® Gel net revenues of $101.9 million, an increase of</description>
</item>
<item>
<title>ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-discuss-third-quarter-2025-financial-results-november-7-2025-8-30</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-discuss-third-quarter-2025-financial-results-november-7-2025-8-30</guid>
<pubDate>Fri, 24 Oct 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release</description>
</item>
<item>
<title>ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-new-day-clinical-trial-results-be-presented-late</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-new-day-clinical-trial-results-be-presented-late</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings PRINCETON, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ANI</description>
</item>
<item>
<title>ANI Pharmaceuticals to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-present-upcoming-investor-conferences-2025-08-25</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-present-upcoming-investor-conferences-2025-08-25</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani,</description>
</item>
<item>
<title>ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-reports-record-second-quarter-2025-financial-results-and-raises</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-reports-record-second-quarter-2025-financial-results-and-raises</guid>
<pubDate>Fri, 08 Aug 2025 04:00:00 GMT</pubDate>
<description>Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal</description>
</item>
<item>
<title>ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-discuss-second-quarter-2025-financial-results-august-8-2025-8-30</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-discuss-second-quarter-2025-financial-results-august-8-2025-8-30</guid>
<pubDate>Fri, 01 Aug 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will</description>
</item>
<item>
<title>ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)</title>
<link>https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-results-new-day-clinical-trial-iluvienr-use-patients</link>
<guid isPermaLink="true">https://6ix.com/company/ani-pharmaceuticals-inc/news/ani-pharmaceuticals-announces-results-new-day-clinical-trial-iluvienr-use-patients</guid>
<pubDate>Wed, 23 Jul 2025 04:00:00 GMT</pubDate>
<description>Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled</description>
</item>
</channel>
</rss>